Medicare Coverage With Evidence Development Mandate Expires After Four Years Under Senate Bill
Executive Summary
As CMS brings public attention to process with its national coverage analysis for Alzheimer’s drugs, legislation aims to encourage quick recommendations – and strengthen collaboration with FDA.
You may also be interested in...
Any Medicare Study Requirements For Alzheimer’s Drugs Should Be Time Limited, CMS Told
Alliance for Aging Research worries the studies could drag on as long as the nine years Biogen is allowed for collecting Phase IV clinical data on its Aduhelm.
All Alzheimer’s Eyes On Medicare: CMS Will Take The Lead On Tailoring Access To Aduhelm
Biogen/Eisai’s newly-approved Alzheimer’s drug could be headed to CMS’ Medicare advisory committee, which is chaired by vocal drug pricing reform advocate Peter Bach.
Code Break: Medicare Accelerates ‘J-Code’ Assignment To Boost Uptake Of New Drugs
Manufacturers can apply for permanent Medicare reimbursement codes on a quarterly basis rather than annually going forward to allow for more frequent coding awards. Recently about two dozen drugs, including three biosimilars, received permanent codes earlier than usual.